Improved targeting of brain tumors using dexrazoxane rescue of topoisomerase II combined with supralethal doses of etoposide and teniposide

Clinical Cancer Research

Volumn 4, Issue 6, 1998, Pages 1367-1373

  Holm, Bente ^a,b   Sehested, Maxwell ^b   Jensen, Peter Buhl ^a,b  

^a Rigshospitalet   (Denmark)

^b FINSEN LABORATORY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; RAZOXANE; TENIPOSIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN TUMOR; CENTRAL NERVOUS SYSTEM TUMOR; CONTROLLED STUDY; CYTOTOXICITY; DNA CLEAVAGE; DNA STRAND BREAKAGE; DOSE CALCULATION; ENZYME INHIBITION; GENE TARGETING; HYDROPHILICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

AMSACRINE; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; DNA TOPOISOMERASES, TYPE II; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; MICE; MICE, INBRED STRAINS; RAZOXANE; SURVIVAL RATE; TENIPOSIDE;

EID: 0031802032     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Chen, A. Y., and Liu, L. F. DNA topoisomerases: essential enzymes and lethal targets. Annu. Rev. Pharmacol. Toxicol., 34: 191-218, 1994.
2. Wang, J. C. DNA topoisomerases. Annu. Rev. Biochem, 65: 635-692, 1996.
3. Jensen, P. B., Jensen, P. S., Demant, E. J. F., Friche, E., Sørensen, B. S., Sehested, M., Wassermann, K., Vindeløv, L., Westergaard, O., and Hansen, H. H. Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II. Cancer Res., 51: 5093-5099, 1991.
4. Jensen, P. B., Sørensen, B. S., Demant, E. J. F., Sehested, M., Jensen, P. S., Vindeløv, L., and Hansen, H. H. Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4′-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage. Cancer Res., 50: 3311-3316, 1990.
5. Jensen, P. B., Sørensen, B. S., Sehested, M., Grue, P., Demant, E. J. F., and Hansen, H. H. Targeting the cytotoxicity of topoisomerase II-directed epipodophyllotoxins to tumor cells in acidic environments. Cancer Res., 54: 2959-2964, 1994.
6. Tanabe, K., Ikegami, Y., Ishida, R., and Andoh, T. Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives. Cancer Res., 51: 4903-4908, 1991.
7. Ishida, R., Miki, T., Narita, T., Yui, R., Sato, M., Utsumi, K. R., Tanabe, K., and Andoh, T. Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors. Cancer Res., 51: 4909-4916, 1991.
8. Sehested, M., Jensen, P. B., Sørensen, B. S., Holm, B., Friche, E., and Demant, E. J. F. Antagonistic effect of the cardioprotector (+)-1,2,-bis(3-5-dioxopiperazinyl-lyl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16). Biochem. Pharmacol., 46: 389-393, 1993.
9. Berger, J. M., Gamblin, S. J., Harrison, S. C., and Wang, J. C. Structure and mechanism of DNA topoisomerase II. Nature (Lond.), 379: 225-232, 1996.
10. Berger, J. M., and Wang, J. C. Recent developments in DNA topoisomerase II structure and mechanism. Curr. Opin. Struct. Biol., 6: 84-90, 1996.
11. Roca, J., Berger, J. M., Harrison, S. C., and Wang, J. C. DNA transport by a type II topoisomerase: direct evidence for a two-gate mechanism. Proc. Natl. Acad. Sci. USA, 93: 4057-4062, 1996.
12. Roca, J., Ishida, R., Berger, J. M., Andoh, T., and Wang, J. C. Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp. Proc. Natl. Acad. Sci. USA, 91: 1781-1785, 1994.
13. Roca, J., and Wang, J. C. DNA transport by a type II DNA topoisomerase: evidence in favor of a two-gate mechanism. Cell, 77: 609-616, 1994.
14. Drake, F. H., Hofmann, G. A., Mong, S., Bartus, J. O., Hertzberg, R. P., Johnson, R. K., Mattern, M. R., and Mirabelli, C. K. In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone. Cancer Res., 49: 2578-2583, 1989.
15. Boritzki, T. J., Wolfard, T. S., Besserer, J. A., Jackson, R. C., and Fry, D. W. Inhibition of type II topoisomerase by fostriecin. Biochem. Pharmacol., 37: 4063-4068, 1988.
16. Lee, F. Y. F., Flannery, D. J., and Siemann, D. W. Modulation of the cell cycle-dependent cytotoxicity of adriamycin and 4-hydroperoxycyclophosphamide by novobiocin, an inhibitor of mammalian topoisomerase II. Cancer Res., 52: 3515-3520, 1992.
17. Bojanowski, K., Lelievre, S., Markovits, J., Couprie, J., Jacquemin-Sablon, A., and Larsen, A. K. Suramin is an inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells. Proc. Natl. Acad. Sci. USA, 89: 3025-3029, 1992.
18. Woynarowski, J. M., Sigmund, R. D., and Beerman, T. A. DNA minor groove binding agents interfere with topoisomerase II mediated lesions induced by epipodophyllotoxin derivative VM-26 and acridine derivative m-AMSA in nuclei from L1210 cells. Biochemistry, 28: 3850-3855, 1989.
19. Jensen, P. B., and Sehested, M. DNA topoisomerase II rescue by catalytic inhibitors. A new strategy to improve the antitumor selectivity of etoposide. Biochem. Pharmacol., 54: 755-759, 1997.
20. Holm, B., Jensen, P. B., and Sehested, M. ICRF-187 rescue in etoposide treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumors. Cancer Chemother. Pharmacol., 38: 203-209, 1996.
21. Jensen, P. B., Roed, H., Skovsgaard, T., Friche, E., Vindelrv, L., Hansen, H. H., and Spang-Thomsen, M. Antitumor activity of the two epipodophyllotoxin derivatives VP-16 and VM-26 in preclinical systems: a comparison of in vitro and in vivo drug evaluation. Cancer Chemother. Pharmacol., 27: 194-198, 1990.
22. Chu, E., and Takimoto, C. H. Antimetabolites. Antifolates. In: V. T. DeVita, Jr., S. Hellman, and S. A. Rosenberg (eds.), Cancer: Principles and Practice of Oncology, pp. 358-362, Philadelphia: J. B. Lippincott Co., 1993.
23. Keating, A. Autologous bone marrow transplantation. In: J. O. Armitage and K. H. Antman (eds.), High-dose Cancer Therapy, pp. 172-195. Baltimore: Williams & Wilkins, 1995.
24. Chow, K., and Ross, W. E. Topoisomerase-specific drug sensitivity in relation to cell cycle progression. Mol. Cell. Biol., 7: 3119-3123, 1987.
25. Dombernowsky, P., and Nissen, N. I. Schedule dependency of the antileukemic activity of the podophyllotoxin-derivative VP 16-213 (NSC-141540) in L1210 leukemia. Acta Pathol. Microbiol. Scand., 81: 715-724, 1973.
26. Muggia, F. M. Teniposide: overview of its therapeutic potential in adult cancers. Cancer Chemother. Pharmacol., 34: S127-S133, 1994.
27. Herman, E. H., El-Hage, A. N., Ferrans, V. J., and Witiak, D. T. Reduction by ICRF-187 of acute daunorubicin toxicity in syrian golden hamsters. Res. Commun. Chem. Pathol. Pharmacol., 40: 217-231, 1983.
28. Sehested, M., and Jensen, P. B. Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle. Biochem. Pharmacol., 51: 879-886, 1996.
29. Vogel, C. L., Gorowski, E., Davila, E., Eisenberger, M., Kosinski, J., Agarwal, R. P., and Savaraj, N. Phase I clinical trial and pharmacokinetics of weekly ICRF-187 (NSC 169780) infusion in patients with solid tumors. Invest. New Drugs, 5: 187-198, 1987.
30. Earhart, R. H., Tutsch, K. D., Koeller, J. M., Rodriguez, R., Robins, H. I., Vogel, C. L., Davis, H. L., and Tormey, D. C. Pharmacokinetics of (+)-1,2-di(3,5-dioxopiperazin-1-y1)propane intravenous infusions in adult cancer patients. Cancer Res., 42: 5255-5261, 1982.
31. Jacobsen, P., Srrensen, B., Bastholt, L., Mirza, M. R., Gjedde, S. B., Mouridsen, H. T., and Rose, C. The pharmacokinetics of high-dose epirubicin and of the cardioprotector ADR-529 given together with cyclophosphamide, 5-fluorouracil, and tamoxifen in metastatic breast-cancer patients. Cancer Chemother. Pharmacol., 35: 45-52, 1994.
32. Donehower, R. C., and Rowinsky, E. K. Anticancer drugs. In: V. T. DeVita, Jr., S. Hellman, and S. A. Rosenberg (eds.), Cancer: Principles and Practice of Oncology, pp. 409-418. Philadelphia: J. B. Lippincott Co., 1993.
33. Lee, J. S., Murphy, W. K., Glisson, B. S., Dhingra, H. M., Holoye, P. Y., and Hong, W. K. Primary chemotherapy of brain metastasis in small-cell lung cancer. J. Clin. Oncol., 7: 916-922, 1989.
34. Viens, P., Lagrange, J. L., Thyss, A., Ayela, P., Frenay, M., and Schneider, M. Brain metastases of lung cancer: excessive toxicity of high dose VP-16-213. Eur. J. Cancer Clin. Oncol., 24: 1905-1906, 1988.
35. Postmus, P. E., Haaxma-Reiche, H., Sleijfer, D. T. H., Kirkpatrick, A., McVie, J. G., and Kleisbauer, J. P. High dose etoposide for brain metastases of small cell lung cancer. A phase II study. Br. J. Cancer, 59: 254-256, 1989.
36. Postmus, P. E., Holthuis, J. J. M., Haaxma-Reiche, H., Mulder, N. H., Vencken, L. M., van Oort, W. J., Sleijfer, D. T., and Sluiter, H. J. Penetration of VP 16-213 into cerebrospinal fluid after high-dose intravenous administration. J. Clin. Oncol., 2: 215-220, 1984.
37. Needle, M. V., Molloy, P. T., Geyer, J. R., Hermanliu, A., Belasco, J. B., Goldwein, J. W., Sutton, L., and Phillips, P. C. Phase II study of daily oral etoposide in children with recurrent brain tumors and other solid tumors. Med. Pediatr. Oncol., 29: 28-32, 1997.
38. Relling, M. V., Mahmoud, H. H., Pui, C. H., Sandlund, J. T., Rivera, G. K., Ribeiro, R. C., Crist, W. M., and Evens, W. E. Etoposide achieves potentially cytotoxic concentrations in CSF of children with acute lymphoblastic leukemia. J. Clin. Oncol., 14: 399-404, 1996.
39. Postmus, P. E., Smit, E. F., Haaxma-Reiche, H., van Zandwijk, N., Ardizzoni, A., Quoix, E., Kirkpatrick, A., Sahmoud, T., and Giaccone, G. Teniposide for brain metastases of small-cell lung cancer: a Phase II study. J. Clin. Oncol., 13: 660-665, 1995.
40. M. Hills, P. Armitage, and T. Colton (eds.). Encyclopedia of Biostatistics, pp. 2239-2244. Chichster, England: Wiley & Sons Ltd., 1998.